AUTHORS
Corbin R Azucenas, BS, Aikaterini Voulgaridou, MD2, Lubna Hamdan, MD3, Yasmin Elgammal, MD4, Athina Ntoumaziou, MD5, Mary Risinger, PhD6, Katie Seu, PhD7, Sidharth Sen, PhD8, Leah Kottyan, PhD9, Andrew Volk, PhD10, Nathan Salomonis, PhD11, Theodosia M Kalfa Jr, MD, PhD12
AFFILIATIONS
1 Cincinnati Children's Medical Center Medical Office Building, Cincinnati, Ohio, United States, University of Cincinnati, Cincinnati, Ohio, United States
2 Cincinnati Children's Medical Center Medical Office Building, Cincinnati, Ohio, United States
3 Cincinnati Children's Medical Center Medical Office Building, Cincinnati, Ohio, United States
4 Cincinnati Children's Medical Center Medical Office Building, Cincinnati, Ohio, United States
5 Cincinnati Children's Medical Center Medical Office Building, Cincinnati, Ohio, United States
6 Cincinnati Children's Medical Center Medical Office Building, Cincinnati, Ohio, United States
7 Cincinnati Children's Medical Center Medical Office Building, Cincinnati, Ohio, United States
8 Cincinnati Children's Medical Center Medical Office Building, Cincinnati, Ohio, United States
9 Cincinnati Children's Medical Center Medical Office Building, Cincinnati, Ohio, United States
10 Cincinnati Children's Medical Center Medical Office Building, Cincinnati, Ohio, United States
11 Cincinnati Children's Medical Center Medical Office Building, Cincinnati, Ohio, United States
12 Cincinnati Children's Medical Center Medical Office Building, Cincinnati, Ohio, United States
ABSTRACT
Congenital dyserythropoietic anemia type-Ia (CDA-Ia) is a rare disorder of erythropoiesis, caused by biallelic pathogenic variants in the CDAN1 gene, which encodes Codanin-1, a highly conserved protein. Patients with CDA-Ia frequently require transfusions in utero to survive and present with varying degrees of hemolytic anemia with relative reticulocytopenia, suggesting ineffective erythropoiesis. Bone marrow (BM) pathology reveals erythroid hyperplasia with up to 10% binucleated erythroblasts (EBs), the rare but characteristic finding of internuclear chromatin bridges between nearly-completely separated EBs, and, under transmission electron microscopy (TEM), a “Swiss cheese” appearance in the nuclear heterochromatin of erythroid precursors. Interferon-α exerts a therapeutic effect in patients with CDA-Ia but its mechanism is still poorly understood.
Previous efforts to make an erythroid-specific deletion of CDAN1 in mice utilized the constitutive erythroid-specific Epor-cre recombinase; this model was embryonal lethal by mid-gestation (E12.5–E13.5) due to severe anemia (Noy-Lotan S. et al, 2021 Front Physiol). To circumvent the embryonal lethality caused by Codanin-1 deficiency during fetal development and its associated stress erythropoiesis, we used the erythroid-restricted, inducible Gata1creERT2 mouse model (Yu L. et al, 2021 Blood) to drive deletion of Cdan1 in adult mice, with the goal to investigate the pathological mechanisms of Codanin-1 deficiency in erythropoiesis. We developed Cdan1flox/flox mice utilizing the Cdan1 gene trapped (tm1a) mouse, obtained by the Mutant Mouse Resource & Research Centers, and bred them, as well as Cdan1WT/WT mice, with Gata1creERT2 mice. We induced Cdan1 deletion via weaning 4-week-old Gata1creERT2; Cdan1flox/flox and Gata1creERT2; Cdan1WT/WT mice onto tamoxifen chow; mice were studied after 2 to 3 months on this diet. Whole blood, hind limbs, and spleens were collected for downstream analyses such as complete blood count and BM/spleen cellularity, flow cytometry, and cell sorting. We found that Cdan1∆/∆ mice had a reduction of Cdan1 mRNA expression by 75 ± 16% compared to controls from magnetically separated Ter119+ cells. Cdan1∆/∆ mice developed a macrocytic anemia and splenomegaly. Flow cytometry of Cdan1∆/∆ EBs revealed a reduction in late-stage EBs, compared to controls, not only in the BM, but also in the spleen, maintaining the dyserythropoietic phenotype even in extramedullary erythropoiesis, which failed to compensate for the anemia. We found binucleated EBs and chromatin bridges, characteristic pathological findings of CDA-Ia, in both bone marrow and splenic Cdan1∆/∆ erythroblasts. Under TEM, we observed the “Swiss cheese” phenotype in the heterochromatin of BM and splenic EBs, the hallmark finding of CDA-Ia. Cdan1∆/∆ mice had increased Erfe and Epo mRNA expression in BM and splenic Ter119+ cells and kidney tissue, respectively. We observed an increase in liver nonheme iron stores, suggesting the onset of secondary iron loading likely driven by inappropriate iron demand.
Bulk RNA-sequencing (RNA-seq) of sorted basophilic and orthochromatic Cdan1∆/∆ erythroblasts revealed upregulation of pathways related to Myc targets, DNA repair, nucleoside and ribonucleoside biosynthesis indicating that Cdan1∆/∆ erythroblasts are rapidly cycling and synthesizing DNA, possibly as a compensatory mechanism. To follow-up on these findings, we performed an in vivo cell cycle analysis via injection of EdU (5-Ethynyl-2′-deoxyuridine) and found increased EdU fluorescence intensity in basophilic and polychromatophilic EBs, confirming accelerated cell cycle in Codanin-1-deficient erythroblasts. In parallel work through the CDA Registry (CDAR) of North America (clinicaltrials.gov: NCT02964494), we performed RNA-seq of magnetically isolated reticulocytes from patients with CDA-Ia to obtain surrogate insights into the transcriptomic profile of their precursor populations: Myc targets, DNA repair, and DNA replication pathways were upregulated in patient reticulocytes, similarly to the data in the Cdan1∆/∆ mouse erythroblasts.
In conclusion, we have generated a mouse model that reliably phenocopies CDA-Ia. This mouse model will be used to investigate how loss of Codanin-1 disrupts erythroblast chromatin assembly and condensation and how interferon-α exerts its therapeutic effect correcting anemia in CDA-Ia.
DISCLOSURES
Corbin R Azucenas, BS: No relevant conflicts of interest to declare.